Science Focus
Science Focus
Search
Partnership-with-clicktherapeutics
Boehringer Ingelheim collaborates with Click Therapeutics on prescription-based digital therapeutic to potentially aid in the treatment of schizophrenia
Poultry
Poultry
Biopharmaceuticals: large molecules, enormous potential
Researching, developing and manufacturing biopharmaceuticals is a highly complex and lengthy process, but it has enormous potential.
Knowing the enemy: PRRS and PCVD
The swine industry is constantly vigilant of viruses such as PRRS and PCV2 (PCVD). Learn about prevention, symptoms knowledge, and control measures to make a difference.
Living with type 2 diabetes
People living with type 2 diabetes often suffer a degree of stigma. Learn from Jurjen de Lange what it takes to live a good life despite the disease.
Patient documentary - From diagnosis to everyday living
Blue internal teat sealant now in dairy mastitis portfolio
Boehringer Ingelheim adds blue internal teat sealant to its dairy mastitis portfolio
100-year anniversary of BI in respiratory care
100-year anniversary of Boehringer Ingelheim in respiratory care
Vaccines
Vaccines
Survodutide (BI 456906)
BI 456909
H5N1: Bird flu again. What’s different now?
H5N1: how is avian influenza now? The virus known for affecting wild & domestic birds has been detected in dairy cows in the US. What you need to know.
New production center for Veterinary Public Health
Boehringer Ingelheim invests more than €200 million to establish a strategic production center for Veterinary Public Health in Lyon, France.
Newxxitek™ HVT+ND
The vaccination of 18 to 19-day-old embryos and one-day-old chickens is effective against Marek’s disease and Newcastle disease.
Real stories, real impact: fighting rabies
The danger of rabies is often overlooked. The need for action, unseen. Learn how we can eliminate rabies through leveraging education and dog vaccinations.
VAXXITEK HVT + IBD
To prevent mortality and to reduce clinical signs and lesions of infectious bursal disease. To reduce mortality, clinical signs and lesions of Marek’s disease.
New Partnership to Develop Gene Therapy for Cystic Fibrosis
Boehringer Ingelheim steps into the field of gene therapy with experienced partners to jointly develop first gene therapy for cystic fibrosis
FIBRONEER™ Phase III program initiated
FIBRONEER™ Phase III program initiated globally to evaluate BI 1015550, a novel investigational phosphodiesterase 4B (PDE4B) inhibitor
Avinew
In broiler chickens from the age of one day of age: active immunisation against Newcastle disease to reduce mortality and clinical signs associated with the disease.
Digital Therapeutic
Digital Therapeutic
Jardiance®
Treatment of adults with type 2 diabetes mellitus as an adjunct to diet and exercise.
EMA authorization for Reprocyc ParvoFLEX
Boehringer Ingelheim obtains EMA authorization for Reprocyc® ParvoFLEX, a new porcine parvovirus vaccine
Moving towards a rabies-free Southeast Asia
Boehringer Ingelheim, in collaboration with Eco-Business, has published a comprehensive whitepaper to stop rabies.
Questions and Answers
Answers to common questions from both patients and health care professionals regarding Compassionate Use of experimental medications.
Striving to revolutionize mental health research
World Mental Health Day: Through a precision psychiatry approach and rich pipeline, we are committed to transforming the mental health landscape.